119 related articles for article (PubMed ID: 12006108)
1. High throughput screening for cyanovirin-N mimetics binding to HIV-1 gp41.
Beutler JA; McMahon JB; Johnson TR; O'Keefe BR; Buzzell RA; Robbins D; Gardella R; Wilson J; Boyd MR
J Biomol Screen; 2002 Apr; 7(2):105-10. PubMed ID: 12006108
[TBL] [Abstract][Full Text] [Related]
2. Development of a cyanovirin-N-HIV-1 gp120 binding assay for high throughput screening of natural product extracts by time-resolved fluorescence.
McMahon JB; Beutler JA; O'Keefe BR; Goodrum CB; Myers MA; Boyd MR
J Biomol Screen; 2000 Jun; 5(3):169-76. PubMed ID: 10894760
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.
O'Keefe BR; Shenoy SR; Xie D; Zhang W; Muschik JM; Currens MJ; Chaiken I; Boyd MR
Mol Pharmacol; 2000 Nov; 58(5):982-92. PubMed ID: 11040045
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of anti-HIV peptides from Dorstenia contrajerva and Treculia obovoidea.
Bokesch HR; Charan RD; Meragelman KM; Beutler JA; Gardella R; O'Keefe BR; McKee TC; McMahon JB
FEBS Lett; 2004 Jun; 567(2-3):287-90. PubMed ID: 15178338
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
6. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
[TBL] [Abstract][Full Text] [Related]
7. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
8. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
9. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
10. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
11. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins.
Shenoy SR; O'Keefe BR; Bolmstedt AJ; Cartner LK; Boyd MR
J Pharmacol Exp Ther; 2001 May; 297(2):704-10. PubMed ID: 11303061
[TBL] [Abstract][Full Text] [Related]
12. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1.
Saifuddin M; Hart ML; Gewurz H; Zhang Y; Spear GT
J Gen Virol; 2000 Apr; 81(Pt 4):949-55. PubMed ID: 10725420
[TBL] [Abstract][Full Text] [Related]
13. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
Mori T; Boyd MR
Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
[TBL] [Abstract][Full Text] [Related]
14. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.
Mariner JM; McMahon JB; O'Keefe BR; Nagashima K; Boyd MR
Biochem Biophys Res Commun; 1998 Jul; 248(3):841-5. PubMed ID: 9704015
[TBL] [Abstract][Full Text] [Related]
15. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
[TBL] [Abstract][Full Text] [Related]
16. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.
Boyd MR; Gustafson KR; McMahon JB; Shoemaker RH; O'Keefe BR; Mori T; Gulakowski RJ; Wu L; Rivera MI; Laurencot CM; Currens MJ; Cardellina JH; Buckheit RW; Nara PL; Pannell LK; Sowder RC; Henderson LE
Antimicrob Agents Chemother; 1997 Jul; 41(7):1521-30. PubMed ID: 9210678
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization.
Matei E; Zheng A; Furey W; Rose J; Aiken C; Gronenborn AM
J Biol Chem; 2010 Apr; 285(17):13057-65. PubMed ID: 20147291
[TBL] [Abstract][Full Text] [Related]
18. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
19. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR
Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482
[TBL] [Abstract][Full Text] [Related]
20. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
